Join Us in Transforming Alzheimer's Treatment

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

Start: October, 2026

Last Updated: August, 2026

Status

Active

Phase

2/3

Age

>55 years

Estimated enrollment

400

Study Drug:

Buntanetap

Key Inclusions:

Participation in previous Alzheimer's studies by Annovis

Primary Endpoints:

Safety (24 months of treatment)

Clinicaltrials.gov ID:

NCT07757204

‍TREATMENT

Participants will take buntanetap (30mg) every day for 24 months.

‍

OTHER ENDPOINTS‍

ADAS-Cog13, ADCS-iADL, CDR, MMSE, WAIS-Coding, NPI-12, QoL-AD, CGI-S, and C-SSRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. An independent Data and Safety Monitoring Board (DSMB) will assess treatment safety.

‍

TIMELINE

The study will have a 6-month read-out to measure symptomatic improvement and a 18-month read-out to measure potential disease-modifying response.

‍

Find more information at ClinicalTrials.gov

Dynamic Map Instructions (Delete This)

Don't delete "cru-ncf"-elements

Elements with “cru-ncf-…” classes contain essential attributes required for Dynamic Map to work. Please don't delete these elements.

Style in Webflow, modify in Dynamic Map App

Use the Dynamic Map App from Webflow’s App Store to adjust your map settings. All styling can be managed directly in Webflow. Refer to the Style Guide below the map to customize elements provided by Dynamic Map.

In case of an issue...

... open the Dynamic Map App, click “Refresh,” then “Insert Code,” and follow the provided instructions. If this doesn’t resolve the issue, refer to our Help Center or Customer Support for assistance.

Important Links

Dynamic Map App

Help Center

License Settings

About Dynamic Map for Webflow [by No Code Flow]

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Winter Park

689-488-9124

2233 Lee Rd Suite 101, 32789

Wichita Falls

940-322-1131

3300 Seymour Highway, 76309

Wichita

316-268-6055

1100 N. St. Francis Suite 300, 37214

West Long Branch

732-807-4700

185 State Hwy 36, Bldg A Suite 115, 07764

Toms River

732-341-9500

9 Mule Rd. Suite E8-9, 8755

Syracuse

315-904-5004

1101 Erie Blvd E. Suite 201, 13210

Summerville

216-329-9910

5500 Front St. Suite 230, 29483

Staten Island

718-317-5522

260 Christopher Ln, 10314

Springfield

413-305-1144

95 Frank B. Murray St. 01103

Scottsdale

480-661-5024

9977 N 95th St. Suite 101, 85258

San Marcos

619-485-9892

838 Nordahl Rd. Suite 200, 92069

Sacramento

916-734-9627

1651 Alhambra Blvd #200a

Round Rock

512-218-1222

16040 Park Valley Dr. Suite B100, 78681

Princeton

857-453-8113

256 Bunn Dr. Suite 6, 08540

Portland

503-972-9822

2701 NW Vaughn St. Suite 350, 97210

Plymouth Meeting

920 Germantown Pike Suite 102, 19462

Plymouth

816-820-4109

5 Resnik Road, Suite 205, 02360

Pikesville

410-602-1440

1314 Bedford Ave Ste 205, 21208

Phoenix

602-274-9500

2601 N 3rd St #125, Phoenix, 85004

Orlando

689-488-9112

13563 Narcoossee Rd. Suite 110, 32832

Norwalk

203-838-0070

71 East Ave Ste 1, 06851

New York

646-440-4240

7 Grammercy Park W, 10003

New Port Richey

727-849-4131

5604 Gulf Dr. 34652

Nashville

615-425-0723

321 Homestead Rd, Nashville, 37207

Naples

239-529-6780

3200 Bailey Lane Suite 250, 34102

Moosic

570-346-3686

340 Montage Mountain Rd. 18507

Miami

305-762-1487

5200 NE 2nd Ave, 33137

Metairie

504-321-1700

4420 Conlin St. 70006

Merritt Island

321-305-5015

50 Fortenberry Rd, 32952

Melbourne

407-680-0534

7000 Spyglass Cr #320, 32940

Media

610-891-9024

107 Chesley Dr. Unit 4, 19063

Matthews

704-364-4000

10801 Monroe Road Suite 100, 28105

Maitland

407-500-5252

101 Southhall Lane Suite 150, 32751

Los Angeles

310-794-6191

710 Westwood Plaza

Lakeland

863-940-2087

2135 Harden Blvd, 33803

Lake Worth

561-968-2933

130 John F Kennedy Dr, Suite 203, 33462

Lake Success

516-466-4700

1991 Marcus Ave Suite 110, 11042

Lake Charles

337-602-6642

600 Bayou Pines Blvd. 70601

LadyLake

407-395-4096

8577 NE 138th Ln, 32159

Jacksonville

904-732-6682

4085 University Blvd South Suite 1, 32216

Indianaopolis

317-537-6056

7250 Clearvista Dr, Suite 225, 46256

Independence

216-526-1843

4801 Acorn Dr. OH 44131

Imperial

760-545-0346

2417 Marshall Ave, Suite 1, 92251

Honolulu

808-564-6141

2230 Liliha St. #104, 96817

Hallandale Beach

954-455-5757

911 E. Hallandale Beach Blvd, 33009

Gainesville

678-928-6476

2350 Limestone Pkwy, 30501

Foxboro

781-551-5812

9 Payson Rd. Suite 100, 2035

Fort Myers

239-939-7777

14271 Metropolis Ave, 33912

Flowood

601-420-5812

3531 Lakeland Dr. Brentwood Plaza Suite 1060, 39232

Farmington Hills

248-957-8944

28555 Orchard Lake Rd. Suite 200, 48334

Fairfax

703-520-9703

8316 Arlington Blvd, 22031

Englewood

303-762-6674

701 E. Hampden Ave Suite 510, 80113

Encino

402-238-6395

17777 Ventura Blvd Suite 235, 91316

El Paso

915-974-2200

7100 Westwind Dr. Suite 300C, 79912

East Providence

401-435-8950

1018 Waterman Ave, 02914

Durham

919-668-1538

932 Morreene Rd., 27705

Decatur

404-475-0552

755 Commerce Dr. Suite 200, 30030

Daytona Beach

407-447-4342

2595 West International Speedway Blvd, 32114

Dartmouth

508-300-9803

75 Brandt Ave. 02747

Cordova

901-747-1111

8000 Centerview Pkwy Suite 500, 38018

Clermont

321-500-5252

17309 Pagonia Rd, 34711

Chicago

312-563-4111

1620 W Harrison St

Chicago

312-971-3318

142 E. Ontario St. Suite 1400, 60611

Chicago

773-275-3500

5149 North Ashland Ave, 60640

Chicago

773-997-1000

2923 N. California, Suite 220, 60618

Chesterfield

636-220-1200

17998 Chesterfield Airport Rd. #100, 63005

Chandler

520-239-2636

3190 S. Gilbert Rd. Suite 5, 85286

Centerville

937-208-8298

6611 Clyo Rd. Suite E, 45459

Canoga Park

818-253-8966

22030 Sherman Way Suite 101 and 110, 91303

Brooklyn

718-616-2230

3044 Coney Island Ave Suite 201, 11235

Boca Raton

561-939-0333

1601 Clint Moore Rd. Suite 120, 33487

Bennington

802-447-1409

357 Shields Dr. 05201

Beavercreek

208-346-8900

3572 Dayton- Xenia Rd. Suite 217, 45432

Basalt

970-927-1141

350 Market St. Suite 001, 81621

Aventura

954-889-3257

21000 NE 28th Ave. Suite 204, 33180

Austin

512-407-8628

3215 Steck Ave Suite 202, 78757

Atlantis

30 John F Kennedy Dr, Suite 203, 33462

Arlington

571-749-5807

1635 N George Mason Dr, Arlington, VA 22205

Anaheim

714-999-6688

1020 S. Anaheim Blvd Suite 316, 92805

Amherst

888-555-8884

3980 Sheridan Dr. 14226

Active State

Ask us about our clinical trials

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

IRB approved Alzheimer Study Flyer: Buntanetap in Treating Alzheimer’s and Parkinson’s Disease

The data from our phase 2 study in Alzheimer’s and Parkinson’s patients was published in JPAD (Journal of Prevention of Alzheimer’s Disease) and we have attached the paper. Here is a summary of what we found and why we have progressed our drug into phase 3.
Buntanetap is an orally available small molecule that inhibits the translation of multiple neurotoxic aggregating proteins only under conditions where their translation is elevated – in sick nerve cells. Because it only affects these neurotoxic proteins when they are overexpressed, it restores their normal levels without affecting other proteins and restores homeostasis in the brain.
Both Alzheimer’s disease and Parkinson’s disease have been shown to have mixed pathology and mixed proteinopathy. All four neurotoxic aggregating proteins are present in the brain of Alzheimer and Parkinson patients – Aβ forms plaques, tau forms tangles, alpha-synuclein forms Lewy bodies, and TDP43 forms its aggregates.

Buntanetap inhibits translation of all the above four neurotoxic proteins, thus is well positioned to treat both diseases, which is an advantage compared to removing a single neurotoxic protein alone. In a double-blind, placebo-controlled, multi-center phase 2, study we enrolled 14 early AD and 54 early PD participants who were treated for 25 days with buntanetap or placebo. Buntanetap was safe and well tolerated. Biomarker data indicated a trend in lowering levels of neurotoxic proteins and inflammatory factors and improving axonal integrity and synaptic function in both AD and PD cohorts, confirming target and pathway engagement of buntanetap. Psychometric tests showed statistically significant improvements in ADAS-Cog11 and WAIS coding in AD patients and MDS-UPDRS and WAIS coding in PD patients. These findings support the hypothesis that lowering levels of neurotoxic aggregating proteins leads to stabilization and improvement in cognition and motor function.
Please look us up at ClinicalTrials.gov

Join Us in Transforming Alzheimer's Treatment

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

Dynamic Map Instructions (Delete This)

Don't delete "cru-ncf"-elements

Style in Webflow, modify in Dynamic Map App

In case of an issue...

Important Links

Style Guide – hidden on live site (don't delete or hide)

CMS List Item

Filter Reset / Empty State

Pop-Up

Tooltip

Filter Address Search

Filter Chip

Map Location Pin

Ask us about our clinical trials

IRB approved Alzheimer Study Flyer: Buntanetap in Treating Alzheimer’s and Parkinson’s Disease

Helpful Links

ANNOVIS BIO

CLINICAL TRIALS

INVESTOR RELATIONS

Join Us in Transforming Alzheimer's Treatment

An Open-label Long-term Safety Study of Buntanetap in Participants With AD

Dynamic Map Instructions (Delete This)

Don't delete "cru-ncf"-elements

Style in Webflow, modify in Dynamic Map App

In case of an issue...

Important Links

Style Guide – hidden on live site (don't delete or hide)

CMS List Item

Filter Reset / Empty State

Pop-Up

Tooltip

Filter Address Search

Filter Chip

Map Location Pin

Ask us about our clinical trials

IRB approved Alzheimer Study Flyer: Buntanetap in Treating Alzheimer’s and Parkinson’s Disease

Stay Updated with Annovis Bio, Inc. (NYSE: ANVS)

Helpful Links

ANNOVIS BIO

CLINICAL TRIALS

INVESTOR RELATIONS

Stay Updated with Annovis Bio, Inc.
(NYSE: ANVS)